FOLH1 and neuroendocrine neoplasm: In recent years, we have been witnessing an impressive development in the field of targeted radionuclide therapy, firstly with the approval of 223Ra-therapy for PCa therapy, then followed by the authorization of [177Lu]Lu-oxodotreotide for the management of neuroendocrine tumors (NET) and, even more recently, by the implementation of [177Lu]Lu-PSMA-617 for mCRPC [14,29,30,31].